You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PSA Progression

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Prostate Cancer Trial (Dutasteride, Abiraterone)

Not yet recruiting
  • Prostate Cancer
  • (no location specified)
Jan 30, 2023

Prostate Cancer, Metastatic Prostate Cancer Trial in Tampa (Abiraterone, Enzalutamide, Apalutamide)

Recruiting
  • Prostate Cancer
  • Metastatic Prostate Cancer
  • Tampa, Florida
    Moffitt Cancer Center
Feb 21, 2023

Castration-Resistant Prostate Carcinoma, Hormone-Resistant Prostate Cancer, PSA Progression Trial in Portland (drug, other,

Active, not recruiting
  • Castration-Resistant Prostate Carcinoma
  • +4 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Sep 26, 2022

Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma Trial in Detroit,

Active, not recruiting
  • Castration Levels of Testosterone
  • +4 more
  • Detroit, Michigan
  • +1 more
Aug 30, 2022

Prostate Adenocarcinoma, PSA Level Greater Than 0.2, PSA Level Greater Than or Equal to Two Trial in Palo Alto (procedure,

No longer available
  • Prostate Adenocarcinoma
  • +4 more
  • Computed Tomography
  • +3 more
  • Palo Alto, California
    Stanford Cancer Institute Palo Alto
Jan 6, 2022

Prostate Adenocarcinoma, PSA Progression, Recurrent Prostate Carcinoma Trial in Palo Alto (Gallium Ga 68 DOTA-NeoBOMB1, Gallium

Suspended
  • Prostate Adenocarcinoma
  • +2 more
  • Gallium Ga 68 DOTA-NeoBOMB1
  • Gallium Ga 68 PSMA-R2
  • Palo Alto, California
    Stanford Cancer Institute Palo Alto
May 3, 2022

Prostate Cancer, Metastatic Castrate-Resistant Prostate Cancer, PSA Trial in Canada, United States (OGX-427, Abiraterone

Terminated
Has Results
  • Prostate Cancer
  • +2 more
  • Marina Del Rey, California
  • +15 more
Jul 7, 2022

Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory

Active, not recruiting
Has Results
  • Castration Levels of Testosterone
  • +9 more
  • Recombinant EphB4-HSA Fusion Protein
  • Los Angeles, California
  • +2 more
Apr 4, 2022

PSA Level Greater Than 0.03, PSA Progression, Stage I Prostate Adenocarcinoma AJCC (American Joint Committee on Cancer ) v7

Active, not recruiting
  • PSA Level Greater Than 0.03
  • +4 more
  • Antiandrogen Therapy
  • +2 more
  • Los Angeles, California
  • +1 more
Oct 14, 2021

Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7 Trial in United States (Laboratory Biomarker

Active, not recruiting
Has Results
  • Stage I Prostate Adenocarcinoma AJCC v7
  • Stage II Prostate Adenocarcinoma AJCC v7
  • Laboratory Biomarker Analysis
  • +2 more
  • Los Angeles, California
  • +6 more
Oct 6, 2021

Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, PSA Progression Trial in San Francisco (Apalutamide,

Recruiting
  • Castration Levels of Testosterone
  • +3 more
  • San Francisco, California
    University of California, San Francisco
Aug 26, 2021

Prostate Adenocarcinoma, Recurrent Prostate Carcinoma Trial in Houston (Abiraterone Acetate, Bicalutamide, Degarelix)

Active, not recruiting
  • Prostate Adenocarcinoma
  • Recurrent Prostate Carcinoma
  • Abiraterone Acetate
  • +7 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue

Withdrawn
  • Castration Levels of Testosterone
  • +8 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Mar 31, 2021

Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma Trial in Houston,

Active, not recruiting
  • Castration Levels of Testosterone
  • +4 more
  • Abiraterone Acetate
  • +6 more
  • Houston, Texas
  • +2 more
Feb 11, 2022

Cancer of Prostate, Cancer of the Prostate, Tumors, Prostate Trial in Pittsburgh (androgen ablation (AA), DC1 vaccine)

Completed
Has Results
  • Cancer of Prostate
  • +6 more
  • androgen ablation (AA)
  • DC1 vaccine
  • Pittsburgh, Pennsylvania
    University of Pittsburgh Cancer institute
Oct 13, 2020

Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma Trial in Los Angeles

Completed
  • Biochemically Recurrent Prostate Carcinoma
  • +8 more
  • Computed Tomography
  • +3 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Sep 29, 2021

Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone Trial in

Recruiting
  • Castration Levels of Testosterone
  • +4 more
  • HER2Bi-Armed Activated T Cells
  • +2 more
  • Detroit, Michigan
    Wayne State University/Karmanos Cancer Institute
Feb 26, 2021

Psoriatic Arthritis Trial in Hong Kong (Secukinumab, Placebo)

Recruiting
  • Psoriatic Arthritis
  • Hong Kong, Hong Kong
    Department of Medicine and Therapeutics
Jan 27, 2021

Drug Resistance in Metastatic Castration-Resistant Prostate

Completed
  • Castration Levels of Testosterone
  • +5 more
  • Cytology Specimen Collection Procedure
  • +2 more
  • Los Angeles, California
  • +2 more
Sep 24, 2020

Psoriatic Arthritis, Atherosclerosis Trial in Hong Kong (Rosuvastatin, Treat-to-target strategy)

Suspended
  • Psoriatic Arthritis
  • Atherosclerosis
  • Hong Kong, Hong Kong
    Department of Medicine and Therapeutics
Jul 14, 2020

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Nanjing (6-month course of antiandrogen drugs, Long-term course of

Recruiting
  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
  • 6-month course of antiandrogen drugs
  • Long-term course of antiandrogen drugs
  • Nanjing, Jiangsu, China
    Urology dpt, First Affiliated Hospital of Nanjing Medical Univer
Jul 13, 2023

Progressive Metastatic Prostate Cancer Trial in Worldwide (Enzalutamide, Placebo)

Active, not recruiting
Has Results
  • Progressive Metastatic Prostate Cancer
  • Beijing, China
  • +46 more
Jan 13, 2023

Metastatic Hormone-Sensitive Prostate Cancer Trial (Rezvilutamide, Rezvilutamide plus abiraterone, Continue previous treatment)

Not yet recruiting
  • Metastatic Hormone-Sensitive Prostate Cancer
  • (no location specified)
Nov 10, 2023

Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Tumors, Prostate Cancer Recurrent Trial (lorigerlimab,

Not yet recruiting
  • Androgen-Independent Prostatic Cancer
  • +8 more
  • lorigerlimab
  • +2 more
  • (no location specified)
May 4, 2023

Metastatic Castration-resistant Prostate Cancer Trial in Salt Lake City (Bortezomib)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Salt Lake City, Utah
    Huntsman Cancer Institute/University of Utah
Sep 7, 2023